公开(公告)号：US20160052937A1

公开(公告)日：2016-02-25

申请号：US14830970

申请日：2015-08-20

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mamoru Takaishi ,  Nobuhiro Sato ,  Takafumi Motoki ,  Tomoyuki Shibuguchi

IPC: C07D498/04

CPC classification number: C07D498/04

Abstract: A compound represented by formula (I): wherein R is a methyl group or the like, R1 is a fluorine atom or the like, R2 is a hydrogen atom or a fluorine atom, R3 is a hydrogen atom, R4 is an ethyl group or the like, or a pharmaceutically acceptable salt thereof.

Abstract translation: 由式（I）表示的化合物：其中R是甲基等，R 1是氟原子等，R 2是氢原子或氟原子，R 3是氢原子，R 4是乙基或 或其药学上可接受的盐。

公开(公告)号：US20140243316A1

公开(公告)日：2014-08-28

申请号：US14190356

申请日：2014-02-26

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mamoru Takaishi ,  Nobuhiro Sato ,  Tomoyuki Shibuguchi ,  Takafumi Motoki ,  Yoshinori Takahashi ,  Takeo Sasaki ,  Alan Braunton

IPC: C07D498/04

CPC classification number: C07D498/04

Abstract: A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof works as an mGluR2 antagonist, and is applicable as a therapeutic agent for neurological disorders related to glutamate dysfunction and diseases involving the mGluR2, such as Alzheimer's disease: wherein R is a hydrogen atom, a C1-6 alkyl group or the like, R1 is a C1-6 alkyl group, a C1-6 alkoxy group or the like, R2 is a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or the like, R3 is a hydrogen atom, a C1-6 alkyl group or the like, and R4 is a C1-6 alkyl group or the like.

Abstract translation: 由下式（I）表示的化合物或其药学上可接受的盐作为mGluR2拮抗剂起作用，可用作与谷氨酸功能障碍相关的神经障碍和涉及mGluR2的疾病如阿尔茨海默氏病的治疗剂：其中R为 氢原子，C 1-6烷基等，R 1为C 1-6烷基，C 1-6烷氧基等，R 2为卤素原子，C 1-6烷基，C 1-6 烷氧基等，R3是氢原子，C1-6烷基等，R4是C1-6烷基等。

公开(公告)号：US09738656B2

公开(公告)日：2017-08-22

申请号：US15346912

申请日：2016-11-09

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Toshiki Kurokawa ,  Yu Yoshida ,  Kogyoku Shin ,  Yoshihisa Kobayashi ,  Hironori Fukumoto ,  Kunitoshi Takeda ,  Yoshiaki Ohashi ,  Makoto Kotake ,  Tomoyuki Shibuguchi ,  Toru Watanabe ,  Yoichi Kita ,  Shinsuke Hirota ,  Takashi Fukuyama ,  Yasuaki Kamada

IPC: C07D491/147 ,  C07D491/052

CPC classification number: C07D491/147 ,  C07D491/052

Abstract: Compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof:

公开(公告)号：US20170137436A1

公开(公告)日：2017-05-18

申请号：US15346912

申请日：2016-11-09

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Toshiki Kurokawa ,  Yu Yoshida ,  Kogyoku Shin ,  Yoshihisa Kobayashi ,  Hironori Fukumoto ,  Kunitoshi Takeda ,  Yoshiaki Ohashi ,  Makoto Kotake ,  Tomoyuki Shibuguchi ,  Toru Watanabe ,  Yoichi Kita ,  Shinsuke Hirota ,  Takashi Fukuyama ,  Yasuaki Kamada

IPC: C07D491/147 ,  C07D491/052

CPC classification number: C07D491/147 ,  C07D491/052

Abstract: Compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof:

公开(公告)号：US09458176B2

公开(公告)日：2016-10-04

申请号：US14190356

申请日：2014-02-26

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mamoru Takaishi ,  Nobuhiro Sato ,  Tomoyuki Shibuguchi ,  Takafumi Motoki ,  Yoshinori Takahashi ,  Takeo Sasaki ,  Alan Braunton

IPC: A61K31/553 ,  C07D498/04

CPC classification number: C07D498/04

Abstract: A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof works as an mGluR2 antagonist, and is applicable as a therapeutic agent for neurological disorders related to glutamate dysfunction and diseases involving the mGluR2, such as Alzheimer's disease: wherein R is a hydrogen atom, a C1-6 alkyl group or the like, R1 is a C1-6 alkyl group, a C1-6 alkoxy group or the like, R2 is a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or the like, R3 is a hydrogen atom, a C1-6 alkyl group or the like, and R4 is a C1-6 alkyl group or the like.